Published in:
01-03-2021 | Guillain-Barré Syndrome | Letter to the Editor
Optic neuritis associated with sunitinib
Authors:
Seunghee Na, Taewon Kim
Published in:
Neurological Sciences
|
Issue 3/2021
Login to get access
Excerpt
Sunitinib malate is a receptor tyrosine kinase inhibitor commonly used to control angiogenesis and proliferation in cancer. Fatigue, gastrointestinal symptoms, hypertension, and myelosuppression are common adverse effects of sunitinib and are usually manageable. Although adverse neurological effects associated with sunitinib are rare [
1], serious and unexpectable adverse reactions can be seen with widespread use of targeted anticancer therapies. Herein, we describe a rare case of optic neuritis (ON) in a patient with metastatic renal cell carcinoma treated with sunitinib. …